These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24507530)

  • 21. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
    Polman CH; Dahlke F; Thompson AJ; Ghazi M; Kappos L; Miltenburger C; Pozilli C
    Mult Scler; 1995; 1 Suppl 1():S51-4. PubMed ID: 9345400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes assessment in multiple sclerosis.
    Rudick R; Antel J; Confavreux C; Cutter G; Ellison G; Fischer J; Lublin F; Miller A; Petkau J; Rao S; Reingold S; Syndulko K; Thompson A; Wallenberg J; Weinshenker B; Willoughby E
    Ann Neurol; 1996 Sep; 40(3):469-79. PubMed ID: 8797541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant.
    Mallinckrodt C; Chuang-Stein C; McSorley P; Schwartz J; Archibald DG; Perahia DG; Detke MJ; Alphs L
    Pharm Stat; 2007; 6(1):9-22. PubMed ID: 17238129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.
    Bermel RA; Fisher E; Cohen JA
    Neuroimaging Clin N Am; 2008 Nov; 18(4):687-701, xi. PubMed ID: 19068409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome measures in multiple sclerosis.
    Amato MP; Portaccio E
    J Neurol Sci; 2007 Aug; 259(1-2):118-22. PubMed ID: 17376487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive design in clinical research: issues, opportunities, and recommendations.
    Chang M; Chow SC; Pong A
    J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the efficiency of clinical trials in multiple sclerosis.
    Marrie RA; Sormani MP; Apap Mangion S; Bovis F; Cheung WY; Cutter GR; Feys P; Hill MD; Koch MW; McCreary M; Mowry EM; Park JJ; Piehl F; Salter A; Chataway J
    Mult Scler; 2023 Aug; 29(9):1136-1148. PubMed ID: 37555492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian adaptive clinical trials: a dream for statisticians only?
    Chevret S
    Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The changing face of multiple sclerosis clinical trial populations.
    Uitdehaag BM; Barkhof F; Coyle PK; Gardner JD; Jeffery DR; Mikol DD
    Curr Med Res Opin; 2011 Aug; 27(8):1529-37. PubMed ID: 21671851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR; Feldman BM; Pope JE; Tomlinson GA
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statistical methods for evaluating multiple sclerosis therapies.
    Petkau J
    Semin Neurol; 1998; 18(3):351-75. PubMed ID: 9817539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.
    Bergamaschi R
    Expert Rev Neurother; 2006 Mar; 6(3):357-64. PubMed ID: 16533140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptive methods: when and how should they be used in clinical trials?
    Porcher R; Lecocq B; Vray M;
    Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.